About CJC-1295 NO DAC + Ipamorelin
This blend combines CJC-1295 NO DAC (modified GRF 1–29), a GHRH-receptor agonist, with ipamorelin, a ghrelin-receptor (GHS-R1a) agonist. The two peptides stimulate growth hormone release through complementary receptor mechanisms: GHRH-receptor activation primes somatotrophs, while ghrelin-receptor signaling adds a parallel secretagogue input, a combination commonly studied for additive effects on growth hormone output and downstream IGF-1 responses. Researchers use this fixed-ratio blend to simplify formulation logistics in long-term preclinical protocols and to examine synergy between the two pathways. Blend quality requires more than individual peptide purity: accurate stoichiometry, absence of cross-contamination, and physical compatibility after lyophilization all affect reproducibility. Shandong Shengyuan prepares the blend from individually certified components, confirms component identity and ratio by LC-MS, and reports 99.3% combined RP-HPLC purity or higher. The lyophilized product is provided for research use only and is not intended for human or veterinary use.
Research Applications
- Combined GHS-R1a and GHRH assays
- GH synergy studies
- Longitudinal IGF-1 research
- Secretagogue pathway crosstalk
- Preclinical GH axis protocols
Quality & Documentation
Every batch of CJC-1295 NO DAC + Ipamorelin is manufactured under our documented quality system and released with a Certificate of Analysis covering HPLC purity, mass spectrometry identity, peptide content, water content, and endotoxin. The batch code on your vial can be verified online in the COA lookup section of this site.
Tesamorelin
Sermorelin Acetate
Ipamorelin